1. Results: Significant improvement of dissolution of tolbutamide was found.

2. Tolbutamide , indomethacin and diclofenac interacted with each other, resulting in the decreased formation of metabolites catalyzed by CYP2C9.

3. P450 2C9 substrates mainly include tolbutamide, phenytoin, S-warfarin, fluoxetine, and losartan.

4. Objective: To change the dissolution of the tolbutamide tablet by adding L-HPC.

5. Methods: L-HPC was added into tolbutamide and its dissolution was measured.

6. An increased risk of cardiovascular death was associated to treatment with glimeperide, glibenclamide, glipizide, and tolbutamide when compared with metformin (Figure).

7. Objective To investigate the influence of CYP2C9 polymorphism on the pharmacokinetic of tolbutamide metabolism.

8. Conclusion CYP2C9 genetic polymorphism has a significant influence on the pharmacokinetics of tolbutamide. Pharmacogenomic study will be helpful in guiding rational and individualized medication.

9. AIM To establish a reverse phase high-performance liquid chromatography (RP-HPLC)method to determine the level of tolbutamide in human plasma.